Business Wire

CA-C3.AI

25.2.2021 15:02:10 CET | Business Wire | Press release

Share
C3 AI Awarded Robust Omnibus U.S. Patent for End-to-End Enterprise AI Platform

C3 AI today announced that it was awarded a broad-ranging omnibus patent for the company’s end-to-end enterprise AI solution, C3 AI® Suite, further solidifying the company’s position as a leading enterprise AI software provider for accelerating digital transformation, as well as strengthening C3 AI’s intellectual property and competitive advantage.

The newly issued U.S. patent (No.10,817,530) was granted for “systems, methods, and devices for an enterprise AI application development platform.” The patent encompasses not only advanced data processing and AI application development, but also the extensive array of techniques necessary to build an end-to-end enterprise AI platform, including C3 AI’s unique model-driven architecture.

“This patent is the most significant and substantial we have been awarded to date,” said Thomas M. Siebel, CEO of C3 AI. "When we filed years ago, no one else conceived of a comprehensive, end-to-end solution with a model-driven architecture that accelerates the delivery and reduces the complexity of developing and operating enterprise AI applications. This sweeping patent further extends our leadership and maturity in this market as well as our commitment to protect our IP and our customers, ensuring their ability to rapidly deploy and scale AI with confidence to drive high-value outcomes across their business."

The comprehensive patent protects many methods and techniques that enable the development of enterprise AI applications, including:

  • Use of a model-driven architecture for the “design, development, deployment, and operation of next-generation cyber-physical software applications and business processes”
  • The “application of advanced data aggregation methods, data persistence methods, data analytics, and machine learning methods”
  • Methods for “implementing abstraction and continuous processing of the aggregated data using a model-driven architecture”
  • Embedding capabilities “in a model-driven architecture type system to recommend actions based on real-time analysis of petabyte-scale data sets and telemetry data from millions to billions of endpoints”
  • The use of an ontology, or canonical data mode, that “comprises conceptual domain models of various attributes and processes related to different entities or domains,” wherein “the various attributes and processes comprise persistence, data representations, data interrelationships, computing processes, or machine learning algorithms” and “is extensible to allow users of said application development platform to integrate new data formats”
  • A standardized data format that “comprises an aggregation and correlation of two or more data formats associated with the plurality of data stores, while ensuring automatic and guaranteed referential integrity of the underlying two or more data formats,” wherein “the standardized data format is automatically exposed and accessible through RESTful interfaces”
  • “A method comprising: storing time-series data in a key-value store and non-time-series data in a relational database; implementing, on an application development platform, abstraction over a plurality of data stores comprising the key-value store and the relational database, wherein the abstraction comprises a metadata-based mapping framework over a plurality of data formats associated with the plurality of data stores.”

“This appears to be a seminal patent,” said Bruce Sewell, a C3 AI director, and former general counsel of Apple and Intel. “A close reading reveals a number of fundamental concepts that appear both necessary and sufficient to deploy an enterprise AI application.”

C3 AI has invested over a decade building a leading platform that brings enterprise AI solutions across industries at global, industrial scale to drive digital transformation. The C3 AI Suite is a scalable, production-ready enterprise AI solution that enables organizations to rapidly design, develop, and deploy enterprise-scale AI applications on any public, private, or hybrid cloud environment. It allows organizations to integrate and unify massive, fragmented data sets from disparate enterprise and extraprise data stores and sensors, and apply machine learning algorithms to generate predictive insights that improve efficiency, reduce costs, increase revenue, enhance safety, and drive greater profitability.

At the core of the C3 AI Suite is an open, model-driven architecture that significantly simplifies and accelerates data science and the development of enterprise AI applications – from data integration and data management to model development, validation, and deployment. With C3 AI’s model-driven architecture, a small team of developers can build and deploy enterprise-class AI applications in a matter of weeks, with up to 99 percent less code compared to other methods, by using conceptual models of all the elements an application requires.

C3 AI is establishing a Technology Licensing Office to enable third parties to license C3 AI-patented technologies for use in their own products and solutions.

This new patent follows the issue of a patent awarded for advanced methods of data processing. C3 AI holds additional patents in the areas of cybersecurity, fraud detection, and energy data processing.

Patent details are available in the United States Trademark and Patent Office database .

About C3.ai, Inc.

C3.ai, Inc. (NYSE: AI) is a leading provider of enterprise AI software for accelerating digital transformation. C3 AI delivers a family of fully integrated products: C3 AI® Suite, an end-to-end platform for developing, deploying, and operating large-scale AI applications; C3 AI Applications, a portfolio of industry-specific SaaS AI applications; C3 AI CRM, a suite of industry-specific CRM applications designed for AI and machine learning; and C3 AI Ex Machina, a no-code AI solution to apply data science to everyday business problems. The core of the C3 AI offering is an open, model-driven AI architecture that dramatically simplifies data science and application development. Learn more at: www.c3.ai

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye